Small molecule AZ67 does bind to PFKFB3 specifically (Boyd et al., 2015; Emini Veseli et al., 2020) and might be an interesting pharmacological inhibitor for future in vivo atherosclerosis studies, while keeping in mind that effects are likely not mediated by monocytes, macrophages or neutrophils. The gene discussed is PFKFB3; the disease is atherosclerosis.